Rosen's Breast Pathology, 4e

404

Chapter 11

68. Howard JH, Bland KI. Current management and treatment strategies for breast cancer. Curr Opin Obstet Gynecol 2012;24:44–48. 69. Lehman CD. Magnetic resonance imaging in the evaluation of ductal carcinoma in situ . J Natl Cancer Inst Monogr 2010;2010(41):150–151. 70. Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter co- hort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 2010;28:1450–1457. 71. Itakura K, Lessing J, Sakata T, et al. The impact of preoperative mag- netic resonance imaging on surgical treatment and outcomes for duc- tal carcinoma in situ . Clin Breast Cancer 2011;11:33–38. 72. Ashikari R, Hajdu SI, Robbins GF. Intraductal carcinoma of the breast (1960–1969). Cancer 1971;28:1182–1187. 73. Westbrook KC, Gallager HS. Intraductal carcinoma of the breast. A comparative study. Am J Surg 1975;130:667–670. 74. Pandya S, Mackarem G, Lee AKC, et al. Ductal carcinoma in situ : the impact of screening on clinical presentation and pathologic features. Breast J 1998;4:146–151. 75. Rosen PP, Ashikari R, Thaler H, et al. A comparative study of some pathologic features of mammary carcinoma in Tokyo, Japan and New York, USA. Cancer 1977;39:429–434. 76. Patchefsky AS, Schwartz GF, Finkelstein SD, et al. Heterogeneity of intraductal carcinoma of the breast. Cancer 1989;63:731–741. 77. Rosen P, Snyder RE, Urban JA, et al. Correlation of suspicious mam- mograms and X-rays of breast biopsies during surgery. Results in 60 cases. Cancer 1973;31:656–660. 78. Snyder R, Rosen P. Radiography of breast specimens. Cancer 1971;28:1608–1611. 79. Rosen PP. Frozen section diagnosis of breast lesions. Recent experi- ence with 556 consecutive biopsies. Ann Surg 1978;187:17–19. 80. Cheng L, Al-Kaisi NK, Liu AY, et al. The results of intraoperative consultations in 181 ductal carcinomas in situ of the breast. Cancer 1997;80:75–79. 81. Rosen PP, Senie R, Schottenfeld D, et al. Noninvasive breast carci- noma: frequency of unsuspected invasion and implication for treat- ment. Ann Surg 1979;189:98–103. 82. Jorns JM, Visscher D, Sabel M, et al. Intraoperative frozen section analysis of margins in breast conserving surgery significantly de- creases reoperative rates: one-year experience at an ambulatory surgi- cal center. Am J Clin Pathol 2012;138:657–669. 83. Tramm T, Zuckerman K, Tavassoli FA. Skip lesion of DIN (DCIS) in the nipple in a case of breast cancer. Int J Surg Pathol 2011;19: 817–821. 84. Tunon-de-Lara C, André G, Macgrogan G, et al. Ductal carcinoma in situ of the breast: influence of age on diagnostic, therapeutic, and prognostic features. Retrospective study of 812 patients. Ann Surg On- col 2011;18:1372–1379. 85. Bayraktar S, Elsayegh N, Gutierrez Barrera AM, et al. Predictive fac- tors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ . Cancer 2012;118:1515–1522. 86. Bellamy COC, McDonald C, Salter DM, et al. Noninvasive ductal car- cinoma of the breast: the relevance of histologic categorization. Hum Pathol 1993;24:16–23. 87. Silverstein MJ, Waisman JR, Gamagami P, et al. Intraductal carcinoma of the breast (208 cases): clinical factors influencing treatment choice. Cancer 1990;66:102–108. 88. Brown PW, Silverman J, Owens E, et al. Intraductal “noninfiltrating” carcinoma of the breast. Arch Surg 1976;111:1063–1067. 89. Urban JA. Biopsy of the “normal” breast in treating breast cancer. Surg Clin North Am 1969;49:291–301. 90. Ringberg A, Palmer B, Linell F. The contralateral breast at reconstruc- tive surgery after breast cancer operation—a histological study. Breast Cancer Res Treat 1982;2:151–161. 91. GriffinA, Frazee RC. Treatment of intraductal breast cancer—noncomedo type. Am Surg 1993;59:106–109. 92. Schuh ME, Nemoto T, Penetrante RB, et al. Intraductal carcinoma. Analysis of presentation, pathologic findings, and outcome of disease. Arch Surg 1986;121:1303–1307. 93. Schwartz GF, Patchefsky AS, Finklestein SD, et al. Nonpalpable in situ ductal carcinoma of the breast. Predictors of multicentricity and mi- croinvasion and implications for treatment. Arch Surg 1989;124:29–32. 94. Habel LA, Moe RE, Daling JR, et al. Risk of contralateral breast can- cer among women with carcinoma in situ of the breast. Ann Surg 1997;225:69–75.

95. Webber BL, Heise H, Neifeld JP, et al. Risk of subsequent contralateral breast carcinoma in a population of patients with in situ breast carci- noma. Cancer 1981;47:2928–2932. 96. Gump FE, Jicha DL, Ozello L. Ductal carcinoma in situ (DCIS): a re- vised concept. Surgery 1987;102:790–795. 97. Andersen JA, Nielsen M, Blichert-Toft M. The growth pattern of in situ carcinoma in the female breast. Acta Oncol 1988;27:739–743. 98. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975;55:231–273. 99. Barsky SH, Siegal GP, Jannotta F, et al. Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest 1983;49:140–147. 100. Henning K, Berndt A, Katenkamp D, et al. Loss of laminin-5 in the epithelium-stroma interface: an immunohistochemical marker of malignancy in epithelial lesions of the breast. Histopathology 1999;34:305–309. 101. Bose S, Lesser ML, Norton L, et al. Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med 1996;100:81–85. 102. Sternlicht MD, Kedeshian P, Shao ZM, et al. The human myoepithelial cell is a natural tumor suppressor. Clin Cancer Res 1997;3:1949–1958. 103. Barsky SH. Myoepithelial mRNA expression profiling reveals a com- mon tumor-suppressor phenotype. Exp Mol Pathol 2003;74:113–122. 104. Nguyen M, Lee MC, Wang JL, et al. The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype. Oncogene 2000;19:3449–3459. 105. Shao ZM, Nguyen M. Alpaugh ML, et al. The human myoepithelial cell exerts antiproliferative effects on breast carcinoma cells character- ized by p21WAF1/CIP1 induction, G2/M arrest, and apoptosis. Exp Cell Res 1998;241:394–403. 106. Zou Z, Anisowicz A, Hendrix MJ, et al. Maspin, a serpin with tumor- suppressing activity in human mammary epithelial cells. Science 1994;263:526–529. 107. Adriance MC, Inman JL, Peterson OW, et al. Myoepithelial cells: good fences make good neighbors. Breast Cancer Res 2005;7:190–197. 108. AllinenM, BeroukhimR, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004;6:17–32. 109. SmithMC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004;64:8604–8612. 110. Muller A, Homey B, Soto H, et al. Involvement of chemokine recep- tors in breast cancer metastasis. Nature 2001;410:50–56. 111. Kawasaki T, Nakamura S, Sakamoto G, et al. Neuroendocrine duc- tal carcinoma in situ (NE-DCIS) of the breast—comparative clinico- pathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases. Histopathology 2008;53:288–298. 112. Farshid G, Moinfar F, Meredith DJ, et al. Spindle cell ductal carci- noma in situ . An unusual variant of ductal intra-epithelial neoplasia that simulates ductal hyperplasia or a myoepithelial proliferation. Vir- chows Arch 2001;439:70–77. 113. Allred DC, Wu Y, Mao S, et al. Ductal carcinoma in situ and the emer- gence of diversity during breast cancer evolution. Clin Cancer Res 2008;14:370–378. 114. Jansen SA. Ductal carcinoma in situ : detection, diagnosis, and char- acterization with magnetic resonance imaging. Semin Ultrasound CT MR 2011;32:306–318. 115. Lennington WJ, Jensen RA, Dalton LW, et al. Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions. Cancer 1994;73:118–124. 116. Azzopardi JG, Ahmed A, Millis RR. Problems in breast pathology . ( Major Problems in Pathology , vol. 11). Philadelphia: W.B. Saunders, 1979:192–203. 117. Castellano I, Marchiò C, Tomatis M, et al. Micropapillary ductal car- cinoma in situ of the breast: an inter-institutional study. Mod Pathol 2010;23:260–269. 118. Aulmann S, Braun L, Mietzsch F, et al. Transitions between flat epi- thelial atypia and low-grade ductal carcinoma in situ of the breast. Am J Surg Pathol 2012;36:1247–1252. 119. Jain RK, Mehta R, Dimitrov R, et al. Atypical ductal hyperplasia: in- terobserver and intraobserver variability. ModPathol 2011;24:917–923. 120. Wen P, Marsh WL. SMMHC-p63 cocktail improves detection of myo- epithelial layer in high-grade ductal carcinoma in-situ . Mod Pathol 2005;18(Suppl.):54a–55a. 121. Martin HM, Bateman AC, Theaker JM. Calcium oxalate (Weddellite) crystals within ductal carcinoma in situ . J Clin Pathol 1999;52:932.